Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610-0224, USA.
Clin J Am Soc Nephrol. 2011 May;6(5):1155-9. doi: 10.2215/CJN.09671010. Epub 2011 Mar 24.
Calciphylaxis remains a poorly understood life-threatening disorder with limited therapeutic options. Sodium thiosulfate (STS) has reported efficacy, thought to be because solubilizing calcium deposits promote clearance by hemodialysis (HD). Lack of rigorous pharmacokinetic studies makes it problematic for determining proper STS dosing given the expanding range of dialysis prescriptions and intensities.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The purpose of this study was to determine the dosing strategies for STS during different dialysis regimens. Given reported successes using an empiric 25 g, intravenous, 3 times per week after HD, simulations were performed to predict dosing guidelines for alternative, more or less intense dialysis to produce equivalent area under the curve drug exposure. The modeled prescriptions varied HD time from 12 to 40 h/wk over three to six sessions (Q(b) 200 to 400 ml/min, Q(d) 500 to 800 ml/min), and continuous venovenous hemodialysis at low flow rates (Q(b) 100 to 200 ml/min, Q(d) 35 to 50 ml/min), using high-flux polysulfone hemofilters.
Simulations showed a marked variation in STS doses depending on HD frequency and duration. Blood and dialysate flows have a less prominent effect. Assuming no residual renal function, HD prescription permutations caused the dose to vary from 72 to 245 g/wk (70-kg adult), and the simulations provide specific guidelines for clinicians.
Based on the success reported for one STS dosing regimen and assuming area under the curve exposure of STS is proportional to its effect, pharmacokinetic simulations can be used to calculate the dose for alternative, higher or lower intensity dialysis regimens. These strategies are imperative to assure adequate treatment for this mortal disease, as well as to avoid toxicity from excess dosing.
钙化防御仍然是一种理解甚少、危及生命且治疗选择有限的疾病。硫代硫酸钠(STS)已被报道具有疗效,其作用机制可能是由于可溶解钙沉积,从而促进血液透析(HD)清除。由于透析方案和强度的范围不断扩大,缺乏严格的药代动力学研究使得确定适当的 STS 剂量变得很成问题。
设计、设置、参与者和测量:本研究的目的是确定不同透析方案中 STS 的给药策略。鉴于报道称在 HD 后每周静脉注射 25g,共 3 次,可取得成功经验,因此进行了模拟,以预测替代方案、更强或更弱的透析方案的给药指南,以产生等效的药物暴露 AUC。模型处方将 HD 时间从每周 12 至 40 小时分为三个至六个疗程(Q(b) 200 至 400ml/min,Q(d) 500 至 800ml/min),并使用高通量聚砜血液滤器进行低流量连续静脉-静脉血液透析(Q(b) 100 至 200ml/min,Q(d) 35 至 50ml/min)。
模拟结果表明,STS 剂量随 HD 频率和持续时间的变化而显著变化。血液和透析液流量的影响较小。假设没有残余肾功能,HD 处方的变化会导致剂量从每周 72 至 245g 变化(70kg 成人),并且模拟为临床医生提供了具体的指导方针。
基于一种 STS 给药方案的成功经验,并假设 STS 的 AUC 暴露与其疗效成正比,药代动力学模拟可用于计算替代、更高或更低强度透析方案的剂量。这些策略对于确保对这种致命疾病进行充分治疗以及避免过量给药引起的毒性至关重要。